(141 days)
No
The document describes a mechanical device for cardiopulmonary bypass surgery and does not mention any software, algorithms, or data processing that would indicate the use of AI or ML.
Yes
The device is described as an "Oxygenator" intended to "exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during cardiopulmonary bypass surgery," and also includes an integrated heat exchanger to "warm or cool blood," all of which directly contributes to patient care and treatment.
No
The device is an oxygenator used to exchange gases between blood and a gaseous environment during cardiopulmonary bypass surgery. It facilitates gas exchange, filters particles and emboli, and warms/cools blood, none of which are diagnostic functions.
No
The device is a physical medical device (oxygenator, filter, reservoir) used during cardiopulmonary bypass surgery, not a software-only device.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is used to "exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during cardiopulmonary bypass surgery." It also describes functions like filtering blood, warming/cooling blood, and storing blood. These are all direct interactions with the patient's blood outside the body during a surgical procedure.
- IVD Definition: An In Vitro Diagnostic device is defined as a medical device intended for use in the in vitro examination of specimens derived from the human body solely or principally for the purpose of providing information concerning a physiological state, state of health, or disease. This device does not perform in vitro examination of specimens. It is part of an ex vivo (outside the living body) circuit for supporting a patient during surgery.
- Device Description: The description details the physical components and how they function to support cardiopulmonary bypass, not to analyze blood samples for diagnostic purposes.
- Performance Studies: The performance studies focus on the device's ability to handle blood flow, filter particles, remove air bubbles, and maintain mechanical integrity during simulated use, all related to its function in the cardiopulmonary bypass circuit. There are no studies related to analyzing blood for diagnostic information.
In summary, the Capiox® FX Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir is a device used to support a patient's physiological functions during surgery, not to diagnose a condition by analyzing blood samples.
N/A
Intended Use / Indications for Use
The Capiox® FX Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir is intended to be used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during cardiopulmonary bypass surgery. The integrated arterial filter is intended to filtrate non-biologic particles and emboli and to facilitate air bubble removal from the blood flowing through the cardiopulmonary bypass circuit.
The integrated heat exchanger is used to warm or cool blood and/or perfusion fluid as it flows through the device.
The hardshell reservoir is used to store blood during extra-corporeal circulation from the venous line and the cardiotomy line. The reservoir contains a venous section that is comprised of a filter and defoamer to facilitate air bubble removal. The cardiotomy section of the reservoir contains a filter to remove particulate matter and a defoamer to facilitate air bubble removal. The 3-liter and 4-liter reservoirs may be used for Vacuum Assisted Drainage procedures and Post Operative Chest Drainage Procedures.
The Capiox® FX15 Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir (both 3-liter and 4-liter) is for use with patients when the required blood flow rate will not exceed 5.0 L/min. The Capiox® FX25 is for use with patients when the required blood flow rate will not exceed 7.0 L/min.
The Capiox® FX Advance Oxygenator/Reservoir/Arterial Filter assemblies can be used in procedures lasting up to 6 hours.
Product codes (comma separated list FDA assigned to the subject device)
DTZ, DTN, DTR, DTM
Device Description
The modified Capiox® FX15 and FX25 Advance Oxygenators (with 4-liter Reservoir) utilize porous fiber technology to facilitate the transfer of gases between a blood-phase environment and a gas-phase environment for the intent of satisfying the gas exchange needs of a patient during cardiopulmonary bypass surgery. A fiber bundle offers the porous membrane surface to sufficiently permit the movement of gases through the walls of the hollow fibers via diffusion.
The modified Capiox® FX15 and FX25 Advance devices have an integrated heat exchanger that is comprised of stainless steel encased in a polycarbonate housing. The stainless steel acts as a heat transfer material that permits heat that is generated from a temperature controlled external water bath to transverse across the walls of the stainless steel to effect the necessary temperature change upon circulating blood.
With respect to the filtration of arterial blood, the modified Capiox® FX15 and FX25 Advance Oxygenators rely upon mechanical entrapment of particulates and emboli within the filter mesh as a means to remove those particulates from the blood.
The design of the subject and predicate devices is nearly identical. No modifications are being made to the oxygenator or arterial filter components of the reservoir component of the devices remain identical to the design of the original reservoir that was cleared by FDA with K140774, except for the following:
- The geometry of the polycarbonate Venous Inlet Port is being modified from an angled . design to a curved design. The curved design for the inlet port will facilitate enhanced air handling within the device.
- . The venous port drop tube within the reservoir is being modified from a straight design at the lower end of the tube to a flared design, which is intended to improve flow dynamics through the reservoir.
- The polyvinyl chloride flexible tubing used in the Reservoir is being changed from PVC . tubing with DEHP plasticizer to PVC tubing with TOTM plasticizer. This change will address growing market concerns with the use of DEHP and to meet pending regulatory requirements in the global market. The modified tubing affects the venous drop tubes, the sampling manifold tubing, the arterial quick disconnect and the arterial purge line tubing.
- . The minimum operating level of the Reservoir will be reduced from 200mL to 150mL.
- The decal-type graduate scale label affixed to the outside surface of the Reservoir is being o increased in length to offer convenience to the user-perfusionist.
The materials that are used in the construction of the Capiox® FX15 and FX25 Advance Oxygenators include nylon, polycarbonate, stainless steel, polyvinyl chloride, polyurethane, polyester, polypropylene, polyethylene terephthalate, polyethylene and X-Coating™.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical studies involving patients are not necessary to demonstrate substantial equivalence of the subject device to the predicate devices. For this submission, Terumo Cardiovascular has completed the following (simulated use) performance evaluations on the reservoir:
- Verification Testing of Curved Inlet Reservoir Connections .
- o Verification Testing of Pressure Drop
- Verification Testing of Hemolysis .
- Verification Testing of Reservoir Venous Filter Defoaming .
- Verification Testing of Clotting Performance .
- Verification Testing of Air Handling Performance o
- Flow Dynamics Evaluation of Curved Inlet Port .
- . Aged Mechanical Integrity Testing
For this submission, it is not necessary to conduct performance testing on the oxygenator/arterial filter module since there have been no changes to the oxygenator/arterial filter. The performance of the oxygenator/arterial filter module is completely independent of the reservoir. Changes made to the reservoir have no impact whatsoever on the performance of the oxygenator.
Performance evaluations have demonstrated substantial equivalence across varying elements of design.
Performance evaluations have demonstrated substantial equivalence between the two materials.
The subject Capiox® FX15 and FX25 Advance devices exhibit equivalent performance to the predicate devices. A series of simulated use testing of the reservoirs demonstrates substantial equivalence between the two designs.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4350 Cardiopulmonary bypass oxygenator.
(a)
Identification. A cardiopulmonary bypass oxygenator is a device used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during open-heart surgery.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions.”
0
Image /page/0/Picture/0 description: The image shows the seal for the Department of Health & Human Services (USA). The seal features the department's name encircling a stylized caduceus symbol. The caduceus is depicted as a series of three interconnected, abstract human profiles. The seal is in black and white.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
November 19, 2015
Terumo Cardiovascular Systems Corporation Jaime Lee Regulatory Affairs Associate 125 Blue Ball Road Elkton, Maryland 21921
Re: K151791
Trade/Device Name: Terumo Capiox FX15 Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir, Terumo Capiox FX25 Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir Regulation Number: 21 CFR 870.4350 Regulation Name: Cardiopulmonary Bypass Oxygenator Regulatory Class: Class II Product Code: DTZ. DTN. DTR. DTM Dated: October 21, 2015 Received: October 22, 2015
Dear Jaime Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR
1
Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
M.A. Hillebrand
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Image /page/2/Picture/0 description: The image shows the Terumo Corporation logo. The logo consists of a green circle with a white "T" inside, followed by the word "TERUMO" in green, sans-serif font. A small registration mark is present to the right of the word.
SECTION 4 - Indications for Use Capiox® FX15 and FX25 Advance Oxygenators with Integrated Arterial Filter and 4-Liter Hardshell Reservoir
510(k) Number (if known): K151791
Device Name: CAPIOX® FX15 and FX25 Advance Oxygenators with Integrated Arterial Filter and Hardshell Reservoir
Indications for Use:
The Capiox® FX Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir is intended to be used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during cardiopulmonary bypass surgery. The integrated arterial filter is intended to filtrate non-biologic particles and emboli and to facilitate air bubble removal from the blood flowing through the cardiopulmonary bypass circuit.
The integrated heat exchanger is used to warm or cool blood and/or perfusion fluid as it flows through the device.
The hardshell reservoir is used to store blood during extra-corporeal circulation from the venous line and the cardiotomy line. The reservoir contains a venous section that is comprised of a filter and defoamer to facilitate air bubble removal. The cardiotomy section of the reservoir contains a filter to remove particulate matter and a defoamer to facilitate air bubble removal. The 3-liter and 4-liter reservoirs may be used for Vacuum Assisted Drainage procedures and Post Operative Chest Drainage Procedures.
The Capiox® FX15 Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir (both 3-liter and 4-liter) is for use with patients when the required blood flow rate will not exceed 5.0 L/min. The Capiox® FX25 is for use with patients when the required blood flow rate will not exceed 7.0 L/min.
The Capiox® FX Advance Oxygenator/Reservoir/Arterial Filter assemblies can be used in procedures lasting up to 6 hours.
NOTE: The indication change that increases the maximum flow rate of the FX15 with the 3-Liter reservoir from 4.0 liters per minute to 5.0 liters per minute has been submitted as a part of Traditional 510(k) application K151389. This Special 510(k) application is solely intended for the FX15 and FX25 oxygenator used with the 4-Liter reservoir. There is no indication change with respect to the 4-Liter reservoir.
XX ___________________________________________________________________________________________________________________________________________________________________________ Prescription Use (Part 21 CFR 801 Subpart D)
OROver-The-Counter Use (Part 21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
3
Submitter Information
This submission was prepared in June 2015 by: Jaime Lee Regulatory Affairs Associate Terumo Cardiovascular Systems Corporation 125 Blue Ball Road Elkton, MD 21921 Telephone: 1-800-262-3304, Ext. 7650 Fax: 410-392-7171
This submission was prepared for: Terumo Cardiovascular Systems Corporation 125 Blue Ball Road Elkton, MD 21921 Facility Registration No. 1124841
| Device Names/Classifications
| Proprietary Name | Classification Name | Common Name |
|---|---|---|
| Capiox® FX15 and FX25 Advance | ||
| Oxygenator with Integrated Arterial | ||
| Filter and Hardshell Reservoir | Cardiopulmonary Bypass | |
| Oxygenator (Code: DTZ) | Oxygenator | |
| Cardiopulmonary Bypass | ||
| Blood Reservoir (Code: DTN) | Blood Reservoir | |
| Cardiopulmonary Bypass | ||
| Heat Exchanger (Code: DTR) | Heat Exchanger | |
| Cardiopulmonary Bypass | ||
| Arterial Line Blood Filter (Code: DTM) | Arterial Filter |
Predicate Device
The device submitted in this 510(k) maintains characteristics that are substantially equivalent in intended use, design, technology/principles of operation, materials and specifications to the following devices:
Terumo® Capiox® FX Hollow Fiber Oxygenator with Integrated Arterial Filter and Hardshell Reservoir - K140774.
Intended Use
The Capiox® FX Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir is intended to be used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during cardiopulmonary bypass surgery. The integrated arterial filter is intended to filtrate non-biologic particles and emboli and to facilitate air bubble removal from the blood flowing through the cardiopulmonary bypass circuit.
The integrated heat exchanger is used to warm or cool blood and/or perfusion fluid as it flows through the device.
The hardshell reservoir is used to store blood during extra-corporeal circulation from the venous line and the cardiotomy line. The reservoir contains a venous section that is comprised of a filter and defoamer to facilitate air bubble removal. The cardiotomy section of the reservoir contains a
4
Image /page/4/Picture/0 description: The image shows the Terumo company logo. The logo consists of a green circle with a stylized "T" inside it, followed by the word "TERUMO" in green, sans-serif capital letters. A small registration mark is present to the right of the word.
filter to remove particulate matter and a defoamer to facilitate air bubble removal. The 3-liter and 4-liter reservoirs may be used for Vacuum Assisted Drainage procedures and Post Operative Chest Drainage Procedures.
The Capiox® FX15 Advance Oxygenator with Integrated Arterial Filter and Hardshell Reservoir (both 3-liter and 4-liter) is for use with patients when the required blood flow rate will not exceed 5.0 L/min. The Capiox® FX25 is for use with patients when the required blood flow rate will not exceed 7.0 L/min.
The Capiox® FX Advance Oxygenator/Reservoir/Arterial Filter assemblies can be used in procedures lasting up to 6 hours.
NOTE: The indication change that increases the maximum flow rate of the FX15 with the 3-Liter reservoir from 4.0 liters per minute to 5.0 liters per minute has been submitted as a part of Traditional 510(k) application K151389. This Special 510(k) application is solely intended for the FX15 and FX25 oxygenator used with the 4-Liter reservoir. There is no indication change with respect to the 4-Liter reservoir.
Principles of Operation and Technology
The modified Capiox® FX15 and FX25 Advance Oxygenators (with 4-liter Reservoir) utilize porous fiber technology to facilitate the transfer of gases between a blood-phase environment and a gas-phase environment for the intent of satisfying the gas exchange needs of a patient during cardiopulmonary bypass surgery. A fiber bundle offers the porous membrane surface to sufficiently permit the movement of gases through the walls of the hollow fibers via diffusion.
The modified Capiox® FX15 and FX25 Advance devices have an integrated heat exchanger that is comprised of stainless steel encased in a polycarbonate housing. The stainless steel acts as a heat transfer material that permits heat that is generated from a temperature controlled external water bath to transverse across the walls of the stainless steel to effect the necessary temperature change upon circulating blood.
With respect to the filtration of arterial blood, the modified Capiox® FX15 and FX25 Advance Oxygenators rely upon mechanical entrapment of particulates and emboli within the filter mesh as a means to remove those particulates from the blood.
Design and Materials
The design of the subject and predicate devices is nearly identical. No modifications are being made to the oxygenator or arterial filter components of the reservoir component of the devices remain identical to the design of the original reservoir that was cleared by FDA with K140774, except for the following:
- The geometry of the polycarbonate Venous Inlet Port is being modified from an angled . design to a curved design. The curved design for the inlet port will facilitate enhanced air handling within the device.
- . The venous port drop tube within the reservoir is being modified from a straight design at the lower end of the tube to a flared design, which is intended to improve flow dynamics through the reservoir.
- The polyvinyl chloride flexible tubing used in the Reservoir is being changed from PVC . tubing with DEHP plasticizer to PVC tubing with TOTM plasticizer. This change will address growing market concerns with the use of DEHP and to meet pending regulatory
5
Image /page/5/Picture/0 description: The image shows the Terumo logo. The logo consists of a green circle with a white "T" inside of it, followed by the word "TERUMO" in green, sans-serif font. The logo is simple and modern, and the green color gives it a sense of health and vitality.
requirements in the global market. The modified tubing affects the venous drop tubes, the sampling manifold tubing, the arterial quick disconnect and the arterial purge line tubing.
- . The minimum operating level of the Reservoir will be reduced from 200mL to 150mL.
- The decal-type graduate scale label affixed to the outside surface of the Reservoir is being o increased in length to offer convenience to the user-perfusionist.
The materials that are used in the construction of the Capiox® FX15 and FX25 Advance Oxygenators include nylon, polycarbonate, stainless steel, polyvinyl chloride, polyurethane, polyester, polypropylene, polyethylene terephthalate, polyethylene and X-Coating™.
Performance Evaluations
Clinical studies involving patients are not necessary to demonstrate substantial equivalence of the subject device to the predicate devices. For this submission, Terumo Cardiovascular has completed the following (simulated use) performance evaluations on the reservoir:
- Verification Testing of Curved Inlet Reservoir Connections .
- o Verification Testing of Pressure Drop
- Verification Testing of Hemolysis .
- Verification Testing of Reservoir Venous Filter Defoaming .
- Verification Testing of Clotting Performance .
- Verification Testing of Air Handling Performance o
- Flow Dynamics Evaluation of Curved Inlet Port .
- . Aged Mechanical Integrity Testing
For this submission, it is not necessary to conduct performance testing on the Note: oxygenator/arterial filter module since there have been no changes to the oxygenator/arterial filter. The performance of the oxygenator/arterial filter module is completely independent of the reservoir. Changes made to the reservoir have no impact whatsoever on the performance of the oxygenator.
Substantial Equivalence Comparison
The information presented in this section depicts a comparison between the subject Capiox® FX15 and FX25 Advance devices and the predicate Terumo Cardiovascular Systems Capiox® FX15 and FX25 Hollow Fiber Oxygenator with Integrated Arterial Filter and Hardshell Reservoir (K140774).
Comparison of Intended Use .
The subject Capiox® FX15 and FX25 Advance devices with the 4-liter Reservoir and the predicate Capiox® FX15 and FX25 devices with a 4-liter Reservoir are identical.
NOTE: The use of the FX15 with the 3-Liter reservoir has been submitted as a part of Traditional 510(k) application K151389. This Special 510(k) application is solely intended for the FX15 and FX25 oxygenator used with the 4-Liter reservoir.
Duration of Use .
The subject Capiox® FX15 and FX25 Advance devices and the predicate devices can be used in procedures lasting up to 6 hours.
Comparison of Labeling .
The subject Capiox® FX15 and FX25 Advance devices and the predicate Capiox® FX15 and FX25 devices are offered with adequate Instructions for Use and other product
6
Image /page/6/Picture/0 description: The image shows the Terumo company logo. The logo consists of a green circle with a stylized "T" inside it, followed by the word "TERUMO" in green, sans-serif capital letters. A small registration mark is present to the right of the word.
labeling as required by regulation. The product IFUs are equivalent and differ only indicating a higher maximum flow rate for the FX15 devices when used with a 3-Liter reservoir – and in some product illustrations.
NOTE: The indication change that increases the maximum flow rate of the FX15 with the 3-Liter reservoir from 4.0 liters per minute to 5.0 liters per minute has been submitted as a part of Traditional 510(k) application K151389. This Special 510(k) application is solely intended for the FX15 and FX25 oxygenator used with the 4-Liter reservoir. There is no indication change with respect to the 4-Liter reservoir.
Comparison of Principles of Operation & Technology .
Both the subject Capiox® FX15 and FX25 Advance Oxygenators and the predicate Capiox® FX15 and FX25 devices utilize the exact same technologies and principles of operation. There are absolutely no differences between the subject and predicate devices with respect to product technology or product operation.
. Comparison of Design
The design of the subject Capiox® FX15 and FX25 Advance Oxygenators are equivalent to the design of the predicate Capiox® FX15 and FX25 devices, except for the following:
- . The geometry of the polycarbonate Venous Inlet Port is being modified from an angled design to a curved design. The curved design for the inlet port will facilitate enhanced air handling within the device.
- . The venous port drop tube within the reservoir is being modified from a straight design at the lower end of the tube to a flared design, which is intended to improve flow dynamics through the reservoir.
Performance evaluations have demonstrated substantial equivalence across varying elements of design.
Comparison of Materials .
The materials of construction between the subject Capiox® FX15 and FX25 Advance Oxygenators and the predicate Capiox® FX15 and FX25 devices are identical with the exception of the plasticizer that is used in the polyvinyl chloride tubing (drop tubes, sampling manifold, purge lines). The subject devices include PVC tubing with TOTM plasticizer while the predicate devices include PVC tubing with DEHP as the plasticizer. Performance evaluations have demonstrated substantial equivalence between the two materials.
- . Comparison of Performance
The subject Capiox® FX15 and FX25 Advance devices exhibit equivalent performance to the predicate devices. A series of simulated use testing of the reservoirs demonstrates substantial equivalence between the two designs.
Substantial Equivalence Statement
The Terumo Cardiovascular Systems Corporation Capiox® FX15 and FX25 Advance devices (with 4-liter Reservoir) and the predicate Capiox® FX15 and FX25 devices (with 4-liter Reservoir) are substantially equivalent in intended use, principles of operation and technology, design, materials, and performance. The noted differences between the subject devices and the predicate devices do not raise new issues of safety and effectiveness.
7
Image /page/7/Picture/0 description: The image shows the Terumo Corporation logo. The logo consists of a green circle with a stylized "T" inside, followed by the word "TERUMO" in green, sans-serif font. The logo is simple and modern, and the green color suggests health and vitality.
Additional Safety Information
- Sterilization conditions have been validated to provide a Sterility Assurance Level (SAL) of . 10°. Terumo further asserts that the ethylene oxide residues will not exceed the maximum residue limits at the time of product distribution.
- . Terumo maintains biocompatibility studies as recommended in the FDA General Program Memorandum #G95-1 (5/1/95): Use of International ISO 10993, "Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing." [External Communicating Devices, Circulating Blood, Limited Exposure (≤ 24 hours) Contact Duration]. The blood contacting materials were found to be biocompatible.
Conclusion
In summary, the Terumo Cardiovascular Systems Corporation Capiox® FX15 and FX25 Advance devices with 4-liter Reservoir are substantially equivalent to the predicate (K140774) Capiox® FX15 and FX25 devices with 4-liter Reservoir with respect to intended use, principles of operation and technology, design, materials, performance, and specifications. It is further noted that any recognized differences do not raise any new issues of patient/user safety or product effectiveness.